Levetiracetam
Product Images NDC 42254-310

6 FDA label images from Rebel Distributors Corp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 42254-310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural Formula (41a781b4 Da67 4650 A99b 593fc34465da 01)

Structural Formula (41a781b4 Da67 4650 A99b 593fc34465da 01)
Chemical structure diagram of the active ingredient Levetiracetam, showing the molecular arrangement including an oxazolidinone ring, an ethyl side chain, and an amide group.*
FDA Label Image

Figure 1. Responder Rate (≥50% Reduction From Baseline) In Study 1 (41a781b4 Da67 4650 A99b 593fc34465da 02)

Figure 1. Responder Rate (≥50% Reduction From Baseline) In Study 1 (41a781b4 Da67 4650 A99b 593fc34465da 02)
A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, showing an increase from 7.4% for placebo to 37.1% for 1000 mg/day and 39.6% for 3000 mg/day dosages of Levetiracetam.*
FDA Label Image

Figure 2. Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (41a781b4 Da67 4650 A99b 593fc34465da 03)

Figure 2. Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (41a781b4 Da67 4650 A99b 593fc34465da 03)
A bar chart depicting the percentage of patients responding to placebo and two dosages of Levetiracetam (1000 mg/day and 2000 mg/day) in a study. The y-axis shows the percentage of patients, and bars indicate approximately 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day doses of Levetiracetam.*
FDA Label Image

Figure 3. Responder Rate (≥50% Reduction From Baseline) In Study 3 (41a781b4 Da67 4650 A99b 593fc34465da 04)

Figure 3. Responder Rate (≥50% Reduction From Baseline) In Study 3 (41a781b4 Da67 4650 A99b 593fc34465da 04)
A bar graph comparing the percentage of patients between two groups: one receiving a placebo and the other receiving Levetiracetam at 3000 mg/day. The placebo group shows 14.4% of patients, while the Levetiracetam group shows 39.4% of patients.*
FDA Label Image

Figure 4. Responder Rate (≥50% Reduction From Baseline) (41a781b4 Da67 4650 A99b 593fc34465da 05)

Figure 4. Responder Rate (≥50% Reduction From Baseline) (41a781b4 Da67 4650 A99b 593fc34465da 05)
Bar graph comparing the percentage of patients in two groups: Placebo (19.6%, n=97) and Levetiracetam (44.6%, n=101). The graph visually represents patient response rates or outcomes associated with the treatment groups.*
FDA Label Image

Levetiracetam 250mg (41a781b4 Da67 4650 A99b 593fc34465da 06)

Levetiracetam 250mg (41a781b4 Da67 4650 A99b 593fc34465da 06)
Levetiracetam 250 mg tablets packaging label from Rebel Distributors Corp. The label indicates 60 film-coated tablets per bottle, each containing levetiracetam USP 250 mg. The tablets are described as blue, oblong-shaped, biconvex with debossed markings. Manufactured by Lupin Limited, Goa, India, the label includes storage instructions and a Physician Partner logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.